Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 8/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | CLK1 | P49759 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553753 | 0.81 | ADORA1 (0.61) | ADORA2AADORA1 | |
| SCHEMBL6134640 | 0.78 | GPR119 (0.47) | ADORA2AADORA1CDK5CDK5R1PDE3B | |
| SCHEMBL5451849 | 0.78 | ADORA1 (0.64) | ADORA2AADORA1CDK5CDK5R1KDM4E | |
| SCHEMBL1553935 | 0.77 | ADORA1 (0.63) | ADORA2AADORA1CDK5CDK5R1PDE3B | |
| SCHEMBL1553233 | 0.76 | ADORA2A (0.62) | ADORA2AADORA1CDK5CDK5R1ALDH1A1 | |
| SCHEMBL1554693 | 0.76 | ADORA1 (0.45) | ADORA2AADORA1KDM4EALDH1A1ADORA2B | |
| SCHEMBL1554448 | 0.75 | ADORA1 (0.52) | ADORA2AADORA1ADORA2BMAP4K4 | |
| SCHEMBL5241771 | 0.74 | ADORA1 (0.49) | ADORA2AADORA1CDK5CDK5R1KDM4E | |
| SCHEMBL13966340 | 0.74 | USP7 (0.37) | ADORA2AADORA1CDK5CDK5R1USP7 | |
| SCHEMBL7467727 | 0.72 | ADORA1 (0.42) | ADORA2AADORA1KDM4EALDH1A1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439175-B1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2011-04-27 | — | — | EP | disclosed |
| EP-2246344-A1 | Pyrimidine compounds and medicinal composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2010-11-03 | — | — | EP | disclosed |
| CN-100519549-C | Pyrimidine compounds and pharmaceutical compositions containing the same | EISAI R&D MAN CO LTD (JP) | 2009-07-29 | — | — | CN | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | HARADA HITOSHI | 2009-01-29 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| US-7396836-B2 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-07-08 | — | — | US | disclosed |
| CN-1575290-A | Pyrimidine derivatives and pharmaceutical compositions containing that compounds | EISAI CO LTD (JP) | 2005-02-02 | — | — | CN | disclosed |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1439175-A1 | PYRIMIDINE COMPOUND AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030023-A1 | PYRIMIDINE COMPOUNDS AND MEDICINAL COMPOSITION THEREOF | CBR3, AHR, HCCS | ADORA2A 539/4885ADORA1 328/4885CDK5 630/4885 |
| US-20050004149-A1 | Pyrimidine compound and medicinal composition thereof | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA1 4/4885CDK5 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.